Long-term follow-up of SKG0106 in people with wet age-related macular degeneration
Follows people with wet macular degeneration who already received SKG0106 for up to 5 years.
Plain-language title generated from the registry record
Registry title: A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Key facts
- Where
- Beijing, Hangzhou, Hefei, Shanghai, and Wenzhou, ChinaSee the 7 sites
Where in China
- Beijing HospitalBeijing, ChinaNot yet recruiting
- Peking Union Medical College HospitalBeijing, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaNot yet recruiting
- The Second Hospital of Anhui Medical UniversityHefei, ChinaNot yet recruiting
- Eye ENT Hospital of Fudan UniversityShanghai, ChinaTaking people
- Xinhua Hospital Affiliated To Shanghai Jiao tong University School of MedicineShanghai, ChinaNot yet recruiting
- Eye Hospital, WMU (Zhejiang Eye Hospital)Wenzhou, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Skyline Therapeutics
- Trial code
- NCT06346600
- Record updated
- 1 September 2026
- Original description
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.Read full original descriptionShow less
A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Inclusion: Subjects who only meet all of the following criteria are eligible for this study:; nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection; Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study.
Exclusion: Subjects who are judged by the investigator unsuitable for this study.